<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Forty patients with high risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) preceded by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were treated with intensive induction and consolidation chemotherapy in a prospective multicenter pilot study </plain></SENT>
<SENT sid="1" pm="."><plain>They were given two cycles of <z:chebi fb="0" ids="28680">cytarabine</z:chebi> 100 mg/m with 12-h intervals on days 1-7 and <z:chebi fb="0" ids="42068">idarubicin</z:chebi> 12 mg/m2 on days 5-7, both intravenously </plain></SENT>
<SENT sid="2" pm="."><plain>Patients who were in remission after these two cycles were given two further cycles of <z:chebi fb="0" ids="28680">cytarabine</z:chebi> on days 1-5 and <z:chebi fb="0" ids="42068">idarubicin</z:chebi> on day 5 </plain></SENT>
<SENT sid="3" pm="."><plain>No maintenance treatment was given </plain></SENT>
<SENT sid="4" pm="."><plain>Eleven out of 19 MDS patients (58%) and 10 out of 21 AML patients (48%), in total 21 out of 40 patients (53%), entered remission </plain></SENT>
<SENT sid="5" pm="."><plain>Eight patients underwent allogeneic bone marrow transplantation </plain></SENT>
<SENT sid="6" pm="."><plain>The follow-up time was 13-48 (median 33) months </plain></SENT>
<SENT sid="7" pm="."><plain>At the time of the analysis, seven patients survived, four patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:hpo ids='HP_0000001'>all</z:hpo> of whom had been treated with bone marrow transplantation (three in continuous remission), and three patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> treated with chemotherapy only (two in continuous remission) </plain></SENT>
<SENT sid="8" pm="."><plain>The median survival of the patients treated with chemotherapy only was 12 months, with the median progression-free survival being 8 months </plain></SENT>
<SENT sid="9" pm="."><plain>In view of the poor prognostic factors of the patients, the remission rate was satisfactory, but the responses as well as the survival were short </plain></SENT>
<SENT sid="10" pm="."><plain>The post-remission treatment needs to be improved </plain></SENT>
</text></document>